Nasseo, Inc. 
Nasseo, Inc. is a medical device company using state of the art surface modification technology to provide patients and clinicians with the next generation of dental and orthopedic implants.
Nasseo’s first product, the Nasseo TiArray™ dental implant system, integrates its proprietary surface modification technology to improve osseointegration. Many dental patients are currently advised not to obtain implants due to high failure rates. These patients include individuals with poor circulatory health issues, such as diabetes and smokers, and individuals who have taken bisphosphonates for an extended period of time. Nasseo’s dental implant system targets this large and growing patient demographic.
Dr. Garrett Cale Smith, PhD, Nasseo’s Co-Founder and CEO, co-invented the technology in an effort to provide better solutions for patients and clinicians. Dr. Smith says, “When implants fail, dentists lose time, money, and patient confidence. The dental industry continues to modify implant surfaces utilizing grit-blasting and coating techniques which do not take into account the structure of bone bonding at the molecular level. Nasseo’s novel surface modification technology aims to provide stronger bone-to-implant bonding resulting in better treatment options for both patients and dentists.”
Nasseo, Inc., has been selected to present at the World’s Best Technology (WBT) Innovation Marketplace 2012, presented by Northrup Grumman. Nasseo is among an elite 130 companies and technology innovators from across the globe that have been chosen by the WBT Selection Committee to present their work at WBT 2012, the premier showcase for innovators in the fields of life science, nanotech, material science and information technologies.
Dr Garrett Smith
Co-Founder, CEO
Novo Seeds 
Novo Seeds is a life science supporting program launched by the Novo Nordisk Foundation and Novo A/S. Novo Seeds has two components, a pre-seed funding capacity and a seed financing fund. Both aim at identifying and developing the unexplored commercial potential present in academic and early stage applied research projects at universities and biotech companies within life science in Scandinavia.
The pre-seed program supports early stage projects based on ideas and results with commercial potential. Funding is given as grants in the same manner as other grants awarded by the Novo Nordisk Foundation.
The seed fund aims at supporting more advanced projects and will operate on commercial terms, i.e. support is given to projects and companies in exchange for ownership or other rights to the companies/projects. Typically, the seed program will invest in newly formed companies that are too early in their development stage to be supported by Novo A/S’ venture capital or other international investors
